Skip to main content

Table 4 Distribution of C4 polymorphisms in Graves' disease patients with or without Graves' ophthalmopathy

From: Association between copy number variation of complement component C4 and Graves' disease

Variations GO P value, individuala
[OR (95%CI), individual]c
P valueb OR (95%CI)d
  No, N (%) Yes, N (%)    
C4 CNV      
4 196 (49.4) 118 (52.0) 0.561 0.396 (Reference)
< 4 92 (23.2) 42 (18.5) 0.188   0.978(0.614-1.558)
> 4 109 (27.5) 67 (29.5) 0.581   1.029(0.687-1.540)
C4A CNV      
2 238 (39.9) 157 (69.2) 0.025 [1.436 (0.994-2.075)] 0.014 (Reference)
< 2 61 (15.4) 18 (7.9) 0.008 [0.590 (0.328-1.059)]   0.549 (0.303-0.998)
> 2 98 (24.7) 52 (22.9) 0.628   0.772 (0.509-1.169)
C4B CNV      
2 229 (57.7) 148 (65.2) 0.074 0.186 (Reference)
< 2 97 (24.4) 46 (20.3) 0.276   0.806 (0.520-1.249)
> 2 71 (17.9) 33 (14.5) 0.316   0.697 (0.430-1.132)
C4 polymorphisms      
A2B2 149 (37.5) 105 (46.3) 0.035 [1.283 (0.900-1.828)] 0.005 (Reference)
A2B1 53 (13.4) 25 (11.0) 0.451   0.796 (0.449-1.411)
A3B2 37 (9.3) 27 (11.9) 0.338   1.067 (0.596-1.912)
A2B3 29 (7.3) 15 (6.6) 0.871   0.734 (0.366-1.476)
A3B1 25 (6.3) 7 (3.1) 0.091   0.374 (0.146-0.960)
A1B2 28 (7.1) 6 (2.6) 0.026 [0.451(0.176-1.160)]   0.374 (0.153-1.056)
Other 65 (16.4) 40 (17.6)    0.894 (0.549-1.455)
  1. Abbreviations: GD, Graves' disease; GO, Graves' ophthalmopathy; CNV, copy number variation; OR, odds ratio; CI, confidence interval; N, number.
  2. aIndividual C4 CNVs and polymorphisms between GD patients with or without GO were evaluated by Fisher's exact test using 2 × 2 contingency tables.
  3. b CNV of C4, C4A and C4B between GD patients with or without GO were evaluated by Fisher's exact test using 3 × 2 contingency tables.C4 polymorphisms between GD patients with or without GO were evaluated by Fisher's exact test using 7 × 2 contingency tables. The p value was estimated by 100,000 Monte Carlo simulations with 99% confidence intervals (CI).
  4. cORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.
  5. dORs and 95% CIs were estimated from logistic regression models adjusting for age, gender, ever received radioiodine treatment, myxedema and vitiligo.